AlphAIalphai — Financial news for AI agents
proactiveinvestors.comSEP 32 min read$BHST

BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing

BioHarvest Sciences (NASDAQ: BHST) plans to list its shares on the Tel Aviv Stock Exchange (TASE) by September 8, 2026, alongside its Nasdaq listing. The company, which develops plant-based molecules, aims to provide Israeli investors with access to its shares. BioHarvest filed to register 22.67 million outstanding shares and up to 5.13 million additional shares. CEO Zaki Rakib stated this move supports the company's growth and global ambitions.

Original reporting
proactiveinvestors.com
Published Sep 3, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing — source image
Source · proactiveinvestors.com
Decision brief

The 30-second read

$BHSTBullishMed
01

Why it matters

The announcement provides new capital‑raising avenues and may improve liquidity, but execution risk remains until the Sep 8 start date.

02

Market read

First‑report of a dual‑listing plan for a small‑cap biotech, offering a modest trading opportunity around the Sep 8, 2026 start.

03

What to watch

Potential costs of maintaining two listings and limited trading history on TASE could temper price gains.

Relevance 6/10Novelty 6/10Timing: listing begins Sep 8 2026

Background

BioHarvest Sciences Inc (NASDAQ:BHST) is a plant‑based molecule developer planning a secondary listing on the Tel Aviv Stock Exchange.

Company-level read

Ticker impact

$BHSTBullishHigh confidence
Context

BioHarvest Sciences announced a dual listing on the Tel Aviv Stock Exchange with trading to start Sep 8, 2026.

Expected impact

Potential modest upside as Israeli investors gain direct access; short-term volatility possible around listing date.

Evidence & confidence

Dual listings are rare for small-cap biotech; the announcement is a primary disclosure and may attract new capital.

Market effects

Sector

May highlight increased interest in Israeli‑origin biotech firms and plant‑based molecule space.

Regional

Could add modest volume to the Tel Aviv market and attract foreign investors to TASE.

Global

Limited to niche biotech investors; not a broad market driver.

Counterpoint

What could challenge this read

The dual listing may dilute existing shareholders and add regulatory complexity, limiting upside.

Key entities

  • company
    BioHarvest Sciences Inc

    NASDAQ‑listed biotech developing plant‑based molecules.

  • exchange
    Tel Aviv Stock Exchange

    Israel's primary securities market where BHST will be listed.

Read at source← All news

Related articles

SEP 3
$AVGOMed

Dow climbs as stocks rebound on earnings, falling Treasury yields

Tiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August

proactiveinvestors.com3 min
AUG 13
$BHSTMed

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences (NASDAQ:BHST) reported Q2 gross profit of $5.1M and a net loss of $3.7M ($0.17/share). Cash was $16.2M at June 30. 2026 revenue guidance was cut to $37M-$40M and EBITDA loss to $3M-$5M. Management tightened CDMO revenue to $4M-$5M and reduced VINIA outlook to $33M-$35M.

yahoo.com6 min
AUG 12
$BHSTMedAI 8/10

BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences (BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with gross profit of $5.1 million and a net loss of $3.7 million ($0.17/share). Cash rose to $16.2 million. The company revised 2026 revenue guidance to $37 million to $40 million and expects consolidated EBITDA losses of $3 million to $5 million, citing a shift toward CDMO growth and a rare fragrance supply agreement.

fool.com6 min
AUG 11
$BHSTMed

BIOHARVEST SCIENCES INC. (BHST): Financial results for Q2 2026

BIOHARVEST SCIENCES INC. (BHST) furnished an SEC Form 6-K — earnings release. BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update - Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable

SEC EDGAR 6-K2 min
AUG 11
Med

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.

yahoo.com6 min
AUG 11
$BHSTMedAI 8/10

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

BioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.

proactiveinvestors.com4 min